Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

IMAGION BIOSYSTEMS LIMITED Director's Dealing 2021

Nov 11, 2021

65092_rns_2021-11-11_e597262b-4270-4bfa-800d-4cd974f1cdcd.pdf

Director's Dealing

Open in viewer

Opens in your device viewer

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Imagion Biosystems Limited ABN 42 616 305 027

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director Mark Van Asten
Date of last notice 11 August 2020

Part 1 ‐ Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest Direct
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances giving rise to the relevant
interest.
N/A
Date of change 10 November 2021
No. of securities held prior to change 1) 470,000 Ordinary Shares
2) 75,000
Listed
IBXO
options
(exercisable at $0.05, expiring on
26 November 2021)
3) 120,000 Listed IBXOA options
(exercisable at $0.03, expiring on
28 April 2023)
4) 250,000
Unlisted
Performance
Options (exercisable at $0.028,
vesting on 1 May 2021, expiring 1
May 2026)
5) 250,000
Unlisted
Performance
Options (exercisable at $0.028,
vesting on 1 May 2022, expiring 1
May 2027)
Class Fully Paid Ordinary Shares
  • See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Number acquired 1) 75,000
Number disposed Nil
Value/Consideration
Note: If consideration is non-cash, provide details and estimated
valuation
1) $3,750
No. of securities held after change 1) 545,000 Ordinary Shares
2) Nil
Listed
IBXO
options
(exercisable at $0.05, expiring on
26 November 2021)
3) 120,000 Listed IBXOA options
(exercisable at $0.03, expiring on
28 April 2023)
4) 250,000
Unlisted
Performance
Options (exercisable at $0.028,
vesting on 1 May 2021, expiring 1
May 2026)
5) 250,000
Unlisted
Performance
Options (exercisable at $0.028,
vesting on 1 May 2022, expiring 1
May 2027)
Nature of change
Example: on-market trade, off-market trade, exercise of options, issue
of securities under dividend reinvestment plan, participation in buy-
back
Exercise of Listed IBXO Options

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract N/A
Nature of interest N/A
Name of registered holder
(if issued securities)
N/A
Date of change N/A
No. and class of securities to which
interest related prior to change
Note: Details are only required for a contract in
relation to which the interest has changed
N/A
Interest acquired N/A
  • See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Interest disposed N/A
Value/Consideration
Note: If consideration is non-cash, provide details
and an estimated valuation
N/A
Interest after change N/A

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed
above traded during a+closed period where prior written
clearance was required?
No
If so, was prior written clearance provided to allow the
trade to proceed during this period?
N/A
If prior written clearance was provided, on what date was
this provided?
N/A
  • See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 3